Urinary excretion of N-acetyl-beta-D-glucosaminidase in newly diagnosed essential hypertensive patients and its changes with effective antihypertensive therapy

International Urology and Nephrology

Volumn 32, Issue 4, 2001, Pages 583-584

  Harmankaya, Özlem ^a   Öztürk, Yahya ^a   Bastürk, Taner ^a   Öbek, Aydogan ^a  

^a SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CILAZAPRIL; CREATININE; ELECTROLYTE; N ACETYL BETA GLUCOSAMINIDASE; UREA;

ADULT; AGED; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; ELECTROLYTE BLOOD LEVEL; ENZYME ACTIVITY; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY TUBULE; KIDNEY TUBULE DAMAGE; KIDNEY TUBULE DISORDER; LETTER; MALE; PROTEIN URINE LEVEL; PROTEINURIA; UREA BLOOD LEVEL; URINARY EXCRETION;

ACETYLGLUCOSAMINIDASE; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CILAZAPRIL; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY; MALE; MIDDLE AGED;

EID: 0035728520     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1014443217611     Document Type: Letter

References (4)

1. Biochemical investigation of urine
2. Urinary N-acetyl-β-D-glucosaminidase (NAG) as an indicator of renal disease
3. Increased excretion of urinary N-acetyl-β-D-glucosaminidase in essential hypertension and its decline with antihypertensive therapy
4. Pathophysiology of increased urinary N-acetyl-β-D-glucosaminidase activity in human hypertension: Effect of cilazapril therapy